Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Venglustat GZ/SAR402671 · 1 trial · 2 indications
Venglustat area under the plasma concentration versus time curve (AUC)
| Arm | Type | Description |
|---|---|---|
| Venglustat | EXPERIMENTAL | Single dose of Venglustat is given, orally under fasting conditions |
| Name | Type | Description |
|---|---|---|
| Venglustat GZ/SAR402671 | DRUG | Pharmaceutical form: Hard Capsule Route of administration: Oral |
Inclusion criteria: For all Subjects: * Male and/or female subjects, between 18 and 79 years of age, inclusive. * Body weight between 50.0 and 115.0 kg, inclusive, if male, and between 40.0 and 100.0 kg, inclusive, if female, body mass index between 18.0 and 34.9 kg/m2, inclusive * Normal electroc...
Venglustat GZ/SAR402671 is an investigational small molecule being studied in nephrology. It is being evaluated in healthy volunteers and in patients with autosomal dominant polycystic kidney disease. The drug is currently in Phase 1 clinical development and is not approved for any use.
Venglustat GZ/SAR402671 is being developed by Sanofi, a company traded under the ticker SNY. The drug is in Phase 1 clinical development for nephrology indications, including autosomal dominant polycystic kidney disease.
Venglustat GZ/SAR402671 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug has received FDA designations including breakthrough therapy, fast track, orphan drug, and priority review.
Venglustat GZ/SAR402671 has one completed Phase 1 clinical trial, NCT03687554, titled "Effect of Venglustat in Patients With Renal Impairment." The trial enrolled 24 participants in the United States, including healthy volunteers and patients with autosomal dominant polycystic kidney disease.
Yes, Venglustat GZ/SAR402671 is also known as SAR402671. The drug is being developed by Sanofi for nephrology indications and is currently in Phase 1 clinical development.